Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 13/20 | 0.73 |
| ▸ | KDM5A | P29375 | 4/20 | 0.55 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.55 |
| ▸ | KDM5C | P41229 | 1/20 | 0.55 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22298179 | 0.88 | PDE9A (0.57) | PDE9AKDM5AKDM5BKDM5CPARP1 | |
| SCHEMBL20870106 | 0.85 | PDE9A (1.00) | PDE9AKDM5AKDM5BKDM5CPDE1C | |
| SCHEMBL24275738 | 0.81 | PDE9A (0.58) | PDE9APDE1C | |
| SCHEMBL22274878 | 0.79 | PDE9A (0.67) | PDE9APDE1CPDE10APARP1 | |
| SCHEMBL22225228 | 0.78 | PDE9A (0.47) | PDE9APDE1C | |
| SCHEMBL24275940 | 0.76 | PDE9A (0.45) | PDE9APDE1C | |
| SCHEMBL22871658 | 0.75 | KDM5A (0.75) | PDE9AKDM5AKDM5BKDM5CPDE10A | |
| SCHEMBL22298103 | 0.74 | KDM5A (0.69) | PDE9AKDM5AKDM5BKDM5CPDE10A | |
| SCHEMBL20870262 | 0.72 | KDM5A (1.00) | PDE9AKDM5AKDM5BKDM5CPARP1 | |
| SCHEMBL4754631 | 0.72 | KDM5A (0.69) | PDE9AKDM5AKDM5BKDM5CPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130366-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-10889591-B2 | PDE9 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
| WO-2019062733-A1 | PDE9 INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889591-B2 | PDE9 inhibitor and use thereof | PDE3A, PDE9A, PDE3B | PDE9A 2/4885KDM5A 1199/4885KDM5B 1464/4885 |
| US-20210130366-A1 | PDE9 INHIBITOR AND USE THEREOF | PDE3A, PDE9A, PDE3B | PDE9A 2/4885KDM5A 1199/4885KDM5B 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.